Brokers Issue Forecasts for ALX Oncology FY2028 Earnings

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Free Report) - Equities researchers at HC Wainwright reduced their FY2028 earnings per share estimates for ALX Oncology in a note issued to investors on Friday, November 8th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $1.43 per share for the year, down from their previous forecast of $1.44. HC Wainwright currently has a "Buy" rating and a $25.00 target price on the stock. The consensus estimate for ALX Oncology's current full-year earnings is ($3.04) per share.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last released its earnings results on Thursday, November 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.78) by $0.20.

A number of other research analysts have also weighed in on the company. Stifel Nicolaus reissued a "hold" rating and set a $3.00 price target (down previously from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Lifesci Capital lowered ALX Oncology from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ALX Oncology in a research note on Monday, August 12th. Finally, UBS Group lowered their target price on shares of ALX Oncology from $25.00 to $4.00 and set a "buy" rating for the company in a report on Friday, August 16th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, ALX Oncology presently has an average rating of "Moderate Buy" and an average price target of $12.50.

ALX Oncology Price Performance

NASDAQ ALXO traded up $0.03 during mid-day trading on Monday, reaching $1.48. 738,432 shares of the stock were exchanged, compared to its average volume of 766,736. The company has a quick ratio of 4.39, a current ratio of 4.39 and a debt-to-equity ratio of 0.06. ALX Oncology has a 1-year low of $1.34 and a 1-year high of $17.83. The business's fifty day simple moving average is $1.76 and its 200 day simple moving average is $5.96.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of ALX Oncology by 207.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,042 shares of the company's stock worth $151,000 after purchasing an additional 56,028 shares during the period. GSA Capital Partners LLP purchased a new stake in ALX Oncology during the third quarter worth approximately $88,000. Los Angeles Capital Management LLC purchased a new stake in ALX Oncology during the third quarter worth approximately $469,000. Privium Fund Management B.V. increased its position in shares of ALX Oncology by 28.2% in the third quarter. Privium Fund Management B.V. now owns 509,059 shares of the company's stock worth $926,000 after acquiring an additional 112,093 shares in the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock valued at $50,000 after acquiring an additional 6,888 shares during the period. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.